Core Viewpoint - The company experienced stable revenue in the first half of 2025, but short-term profits were under pressure due to increased R&D costs and competition in the animal health industry [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved operating revenue of 620 million yuan, a year-on-year increase of 1.28%, indicating relative stability in revenue [1]. - The net profit attributable to shareholders was 60.424 million yuan, a year-on-year decrease of 50.84%, reflecting short-term profit pressure [1]. - The gross profit margin for H1 2025 was 52.24%, down 5.68 percentage points compared to the previous year [1]. Group 2: R&D and Innovation - The company invested 84 million yuan in R&D in H1 2025, accounting for 13.51% of operating revenue, focusing on addressing pain points for farming customers [2]. - In July 2025, the company received clinical trial approval for an mRNA vaccine for feline infectious peritonitis, filling a technological gap in the domestic market [2]. - The company collaborated with research institutions to develop a trivalent inactivated vaccine for bovine foot-and-mouth disease, receiving clinical trial approval in April 2025 [2]. - The company obtained approval for four new veterinary drug certificates, including a novel live vaccine for bovine mycoplasma, which addresses respiratory disease prevention in cattle [2]. Group 3: Market Position and Future Outlook - The company is positioned as a leading animal health enterprise driven by R&D innovation, with a strong pipeline for the African swine fever vaccine expected to significantly support future performance [2]. - Projected net profits for 2025-2027 are estimated at 161 million yuan, 281 million yuan, and 406 million yuan, with corresponding EPS of 0.15 yuan, 0.25 yuan, and 0.37 yuan, indicating growth potential [2].

Core Viewpoint - The company reported a mixed performance in the first half of 2025, with revenue growth but a significant decline in net profit, indicating challenges in a competitive market [1] Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 620 million yuan, a year-on-year increase of 1.28% [1] - The net profit attributable to the parent company was 123 million yuan, a year-on-year decrease of 50.84% [1] - The company experienced increased expense ratios, particularly in sales expenses (+3.63 percentage points) and management expenses (+4.77 percentage points), impacting overall performance [1] Group 2: Market Strategy and Product Performance - The company adopted a price-for-volume strategy to maintain market share in key products, including various vaccines for pigs, with non-key products seeing revenue growth of over 20% [1] - The poultry vaccine segment saw a nearly 40% year-on-year revenue increase due to a professional technical service team targeting key clients [1] - The pet vaccine segment experienced rapid growth in sales of the cat trivalent vaccine through online and offline channel collaboration [1] Group 3: R&D and Innovation - The company focused on R&D, investing 84 million yuan in the first half of 2025, which accounted for 13.51% of its revenue [2] - Significant advancements were made in non-African swine fever vaccines, with a clinical trial approval received for a new vaccine, marking a first in the country [2] - The company also received clinical trial approval for a new mRNA vaccine for feline infectious peritonitis, expected to be launched in 2027-2028, addressing a significant market need [2] - The company obtained new veterinary drug certificates for several vaccines, including a first-of-its-kind live vaccine for bovine mycoplasma [2] Group 4: Future Outlook - The company is expected to see growth in net profit from 137 million yuan in 2025 to 324 million yuan in 2027, with corresponding EPS increasing from 0.12 to 0.29 yuan [3] - The company’s PE ratios are projected to decrease from 73 in 2025 to 31 in 2027, reflecting potential growth and improved market conditions [3] - The company’s innovation capabilities and the anticipated launch of major products are viewed positively for future growth potential [3]

Investment Rating - The investment rating for the company is "Buy" indicating an expected return exceeding 10% relative to the CSI 300 index over the next six months [4][18]. Core Insights - The company achieved a stable revenue of 620 million yuan in H1 2025, reflecting a year-on-year growth of 1.28%, while the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan due to increased R&D expenses and competition in the animal health industry [1][2]. - The company is leading in the development of African swine fever vaccines, having established an integrated R&D platform and received the first clinical trial approval for its subunit vaccine in July 2025 [2][3]. - The company is focused on innovation-driven growth, with R&D expenses amounting to 84 million yuan, representing 13.51% of its revenue. It has made significant advancements in various vaccine technologies and new veterinary drugs [3][4]. Summary by Sections Financial Performance - In H1 2025, the company reported a revenue of 620 million yuan, a slight increase of 1.28% year-on-year. However, net profit fell to 60.42 million yuan, a decline of 50.84% due to rising R&D costs and increased competition leading to lower product prices and gross margin [1]. - The gross margin for H1 2025 was 52.24%, down 5.68 percentage points from the previous year [1]. Vaccine Development - The company is at the forefront of African swine fever vaccine development, with multiple technological routes being explored, including gene deletion vaccines and mRNA vaccines. The subunit vaccine received clinical trial approval from the Ministry of Agriculture and Rural Affairs [2]. - The company has also made strides in developing new vaccines for cats and multi-valent vaccines for cattle, with several clinical trial approvals obtained [3]. R&D and Innovation - The company emphasizes R&D innovation, with a focus on addressing the pain points of livestock customers. The R&D investment in H1 2025 was 84 million yuan, which is 13.51% of its revenue [3]. - Notable achievements include the approval of an mRNA vaccine for feline infectious peritonitis and a multi-valent inactivated vaccine for cattle diseases [3].

Group 1 - The core viewpoint of the news is that YuDe Investment has conducted research on a listed company, focusing on its performance and strategic initiatives in the face of market challenges [1] Group 2 - The company, BioShares, is facing challenges such as macroeconomic upgrades and cyclical adjustments in the breeding industry, but it is maintaining revenue growth through innovation and business model optimization [1] - Key products, including foot-and-mouth disease vaccines and circular ring vaccines, have seen significant sales growth, leading to an increase in market share [1] - The company has achieved breakthroughs in vaccine development, including clinical approval for African swine fever subunit vaccines and mRNA vaccines for feline infectious peritonitis, with expectations for market launch between 2027 and 2028 [1]

Group 1 - The first African swine fever subunit vaccine in China has been approved for clinical trials [1] - The approval was granted to China National Pharmaceutical Group Animal Health Co., Ltd. (referred to as "China National Animal Health") [1] - This marks a significant advancement in the research and development of African swine fever vaccines by China National Animal Health [1]

Group 1 - The core viewpoint indicates that the global supply and demand situation for wheat, corn, rice, and soybeans is adjusting for the 2025/26 fiscal year, with an increase in wheat and rice consumption while production and inventory are being reduced. Conversely, corn production, consumption, and inventory are all being lowered, while soybean production, crushing volume, and ending inventory are being increased [1] - China's imports of corn and other agricultural products are expected to decrease, which may lead to improved planting efficiency due to relatively favorable grain prices [1] - The approval of clinical trials for ASF (African Swine Fever) subunit vaccines may benefit related vaccine companies if trials proceed successfully [1] Group 2 - In the first half of the year, the livestock and poultry farming industry saw a year-on-year increase in slaughter volume and meat production, with poultry meat production increasing by 7.4% and total feed production rising by 7.7%. The number of breeding sows also increased on a month-on-month basis, indicating a sustained improvement in the feed industry [1] - The pet consumption market remains robust, with pet food sales on the Douyin platform increasing by 73.97% year-on-year, highlighting a clear trend of rising domestic brands [1] - The Livestock ETF (159865) tracks the CSI Livestock Index (930707), which selects listed companies involved in feed, livestock farming, vaccines, and veterinary drugs to reflect the overall performance of the livestock industry [1]

Summary of Conference Call Records Industry Overview - The conference call primarily discusses the **pork industry** and the **pet supply chain** market in China, focusing on recent trends, regulatory impacts, and market dynamics. Key Points on the Pork Industry 1. **Pork Price Trends**: Pork prices are on a downward trend due to supply influences, with prices fluctuating around 14 RMB after a brief increase to over 15 RMB in June. This aligns with expectations of high annual output and piglet replenishment rates, indicating limited short-term price increases [1][2]. 2. **Regulatory Impact**: The government aims to stabilize pork supply and prevent price surges, with large farming enterprises playing a crucial role. Stricter measures may be implemented, including environmental regulations and financial controls, to achieve long-term stabilization [1][5]. 3. **Market Dynamics**: The pork industry is undergoing a natural price decline and capacity reduction process. Leading companies like Muyuan Foods are becoming more resilient in the competitive landscape, transitioning from cyclical to value stocks, making them attractive for long-term investment [1][7]. 4. **Production Forecast**: The pork price outlook for Q3 and H2 remains cautious, with high production levels expected to persist. The growth in output is anticipated to keep prices low, as the supply of pigs is not expected to decrease significantly in the short term [4][6]. 5. **Vaccination Developments**: The approval of clinical trials for African swine fever subunit vaccines is a positive development, although the timeline for market availability remains uncertain. This could directly impact companies like BioFeng and Zhongmu [3][15]. Key Points on the Pet Supply Chain 1. **Market Performance**: The pet consumption market showed strong performance in H1 2025, with total spending reaching approximately 77.3 billion RMB, an 8.8% year-on-year increase. Online sales dominate, while offline pet store sales grew only about 1% [8][9]. 2. **Trends in Pet Food**: The pet food market is experiencing product diversification and precision in consumer demand. High-end products and scientific pet care concepts are driving market upgrades, with categories like baked food seeing rapid growth [9][12]. 3. **Emerging Brands**: New brands are quickly rising by meeting consumer needs, indicating a shift towards higher quality and specialized products in the pet food sector [9][12]. 4. **Future Directions**: Domestic pet brands are expected to continue moving towards mid-to-high-end markets, focusing on scientific pet care and product upgrades to maintain growth. The competitive landscape in lower-end markets remains intense [12][14]. 5. **Market Outlook**: The pet industry outlook is optimistic, driven by differentiated products and strong domestic demand. The annual growth rate of new pet owners is stable at around 8%, with online sales growth of 15-16% last year [13][14]. Additional Insights - The pork industry is expected to see a gradual transition towards stable production levels, benefiting leading companies with lower costs and higher certainty in performance [6][7]. - The approval of the African swine fever vaccine is a significant milestone, but the path to market remains complex and uncertain, necessitating close monitoring of developments [15][17]. - The pet supply chain is poised for rapid growth over the next three to five years, presenting a compelling investment opportunity as consumer preferences evolve [14].

Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [45][46]. Core Insights - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, with an increase of 0.74% from July 4 to July 17, 2025, lagging behind the index by approximately 0.93 percentage points [11][14]. - Most sub-sectors recorded positive returns during the same period, with animal health, agricultural product processing, breeding, and planting sectors increasing by 8.71%, 2.56%, 1.42%, and 0.46% respectively, while the fishery and feed sectors saw declines of 1.8% and 4.2% [14][15]. - The overall price-to-book (PB) ratio for the industry is approximately 2.66 times, indicating a slight recovery, but still remains at a historical low, around 59.2% of the valuation center since 2006 [21][22]. Industry Key Data - **Pig Farming**: - The average price of external three yuan pigs decreased from 15.31 CNY/kg to 14.37 CNY/kg between July 4 and July 17, 2025 [24]. - As of June 2025, the breeding sow inventory reached 40.43 million heads, slightly up by 0.02% from the previous month, which is 103.7% of the normal holding capacity of 39 million heads [24]. - The profit from self-breeding pigs is 90.89 CNY/head, while the profit from purchased piglets is -18.66 CNY/head, both showing a decline compared to the previous week [29]. - **Poultry Farming**: - The average price of broiler chicks in major production areas was 1.37 CNY/chick, showing a slight increase, while the average price of layer chicks was 3.88 CNY/chick, which slightly decreased [31]. - The average price of white feather broilers was 6.4 CNY/kg, which has also decreased, with a profit of -2.93 CNY/chick, showing a slight recovery compared to the previous week [34]. - **Feed Costs**: - The spot price of corn was 2409.12 CNY/ton, showing a decline, while soybean meal prices were 2952 CNY/ton, which fluctuated in the last two weeks [26]. Industry Outlook - The report anticipates an overall increase in pig production capacity this year, which may suppress pig prices. The breeding sow inventory has some room for reduction [45]. - The poultry sector continues to face pressure on profitability, with opportunities for marginal improvement [45]. - In the feed sector, there are opportunities arising from increased concentration among leading companies, cost reduction, and overseas expansion [45]. - The domestic pet market is expected to maintain rapid growth, with leading domestic brands likely to see significant growth [45]. Recommended Stocks - Key stocks to focus on include: - Muyuan Foods (002714) - Wens Foodstuff Group (300498) - Shennong Development (002299) - Haida Group (002311) - Bio-Stock (600201) - Zhongchong Co., Ltd. (002891) - Yiyi Co., Ltd. (001206) [46].

Core Viewpoint - The stock of Jinyu Biotechnology Co., Ltd. experienced abnormal trading fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 15 to July 17, 2025, triggering the abnormal fluctuation standards set by the Shanghai Stock Exchange [2][3]. Group 1: Stock Trading Abnormalities - The stock price of Jinyu Biotechnology rose significantly, with a cumulative increase of over 20% during the specified trading days [2][3]. - The company confirmed that its production and operational conditions remain normal, with no significant changes in the external business environment [4]. Group 2: Financial Performance - The company anticipates a net profit attributable to shareholders of between 57 million to 70 million yuan for the first half of 2025, representing a decrease of 52.92 million to 65.92 million yuan compared to the same period last year, which is a year-on-year decline of 43.05% to 53.63% [4]. - The expected net profit after deducting non-recurring gains and losses is projected to be between 30 million to 44 million yuan, reflecting a decrease of 63.86 million to 77.86 million yuan year-on-year, a decline of 59.21% to 72.19% [4]. Group 3: Major Events and Developments - The company’s wholly-owned subsidiary, Jinyu Baoling, received a clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [5][12]. - The vaccine development has involved a cumulative investment of approximately 64 million yuan [13]. Group 4: Shareholder and Management Actions - The company’s major shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., confirmed that there are no undisclosed significant matters related to the company, including major asset restructuring or significant transactions [5][8]. - There were no stock trading activities by the company’s directors, senior management, or major shareholders during the period of abnormal stock price fluctuations [8].

Core Viewpoint - The company has received clinical trial approval for its African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs, marking a significant step in its vaccine development efforts [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., has been granted the clinical trial approval (Approval No: 2025058) for the African swine fever vaccine [1] - The vaccine is specifically designed to prevent African swine fever virus infections, indicating a targeted approach to addressing this critical issue in the livestock industry [1] - The company has invested approximately 64 million yuan in research and development for this vaccine in collaboration with research institutions since 2023 [1] Group 2: Clinical Trial Process - The clinical trials will be conducted at Jinyu Baoling, and the vaccine must complete these trials and undergo registration application before it can be marketed and sold [1] - Approval from regulatory bodies is required after the completion of clinical trials, highlighting the importance of compliance in the pharmaceutical development process [1]